Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2025)

Historic EBT for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$34.4 million.

  • Amylyx Pharmaceuticals' EBT rose 5270.41% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.9 million, marking a year-over-year increase of 4177.51%. This contributed to the annual value of -$302.1 million for FY2024, which is 65645.06% down from last year.
  • Amylyx Pharmaceuticals' EBT amounted to -$34.4 million in Q3 2025, which was up 5270.41% from -$41.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' EBT's 5-year high stood at $24.0 million during Q2 2023, with a 5-year trough of -$118.6 million in Q1 2024.
  • Moreover, its 5-year median value for EBT was -$35.9 million (2025), whereas its average is -$34.0 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' EBT soared by 14454.57% in 2023, and later tumbled by 854982.18% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' EBT (Quarter) stood at -$28.3 million in 2021, then crashed by 52.51% to -$43.2 million in 2022, then soared by 114.98% to $6.5 million in 2023, then plummeted by 689.58% to -$38.2 million in 2024, then increased by 9.94% to -$34.4 million in 2025.
  • Its EBT stands at -$34.4 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$35.9 million for Q1 2025.